Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Breast cancer susceptibility genes 1 and 2 (BRCA1/2) mutations are common in various cancers, including breast and ovarian.
• Inhibiting RAD52 in BRCA2-deficient cancers induces synthetic lethality, highlighting RAD52 as a therapeutic target.

Purpose of the Study:

• To identify compounds that inhibit RAD52 function for targeted cancer therapy.
• To evaluate the efficacy of identified compounds against BRCA2-deficient cancer cells.

Main Methods:

• Virtual screening of 66,608 compounds targeting the RAD52 self-association domain (residues 85-159).
• Biochemical and cell-based assays to assess compound binding and functional inhibition.
• Proliferation assays on BRCA2-deficient cancer cells.

Main Results:

• Identified C791-0064 as a specific inhibitor of RAD52.
• Demonstrated that C791-0064 disrupts RAD52's single-strand annealing activity.
• C791-0064 specifically inhibited the proliferation of BRCA2-deficient cancer cells.

Conclusions:

• C791-0064 is a potent leading compound for developing targeted therapies against BRCA-deficient cancers.
• Further investigation of C791-0064 is warranted for its therapeutic potential in oncology.